Group 1 - The company has established a private equity fund named Wuhan Ruicheng New Drug Technology Achievement Transformation Venture Capital Fund Center (limited partnership) with a total initial investment of 250 million yuan, where the company contributes 75 million yuan as a limited partner [1] - The initial capital of 250 million yuan for the Ruicheng Venture Capital Fund has been fully paid, confirming the actual raised funds [2] - The investment decision was made to leverage the expertise and resources of professional investment institutions while ensuring the stability of the company's main business, with no significant impact on the company's financial and operational performance [2] Group 2 - The company will closely monitor the operation and management of the fund, ensuring the safety and profitability of the investment funds, while fulfilling relevant information disclosure obligations [2] - The fund is subject to registration with the Asset Management Association of China, and its future operations may be influenced by various factors, including economic conditions and regulatory policies [2]